Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Trivedi HL et al. – Bortezomib therapy effectively abrogates anti–HLA antibodies. Hence, removal of antibodies, by proteasome inhibition, represents a new treatment strategy for transplantation and may have benefit in autoimmune–related disease.

Related Articles

Proteasome Inhibitors in Cancer Therapy
Current Drug Targets, 10/23/09    Relevance Score: 91%

TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species
Leukemia, 11/09/09    Relevance Score: 89%

Role of the Ubiquitin-Proteasome Pathway in Down-Regulation of the Gap-Junction Protein Connexin43 by TNF-alpha in Human Corneal Fibroblasts
Investigative Ophthalmology and Visual Science, 11/20/09    Relevance Score: 87%

The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
Journal of Immunology, 11/13/09    Relevance Score: 87%

Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells
Oncogene, 11/05/09    Relevance Score: 87%

Today in Clinical Pharmacology...keeping you current

Effects of endogenous glucocorticoids on allergic inflammation and TH1/TH2 balance in airway allergic disease
Annals of Allergy, Asthma, and Immunology, 12/18/09

Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseases
Current Medical Research and Opinion, 12/18/09

Non-avian-derived hyaluronan for the treatment of osteoarthritis of the knee
Expert Review of Clinical Immunology, 12/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address